7-117590439-G-A
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The NM_000492.4(CFTR):c.1766G>A(p.Ser589Asn) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.00000312 in 1,600,146 control chromosomes in the GnomAD database, with no homozygous occurrence. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S589I) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000492.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.1766G>A | p.Ser589Asn | missense_variant, splice_region_variant | 13/27 | ENST00000003084.11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.1766G>A | p.Ser589Asn | missense_variant, splice_region_variant | 13/27 | 1 | NM_000492.4 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152032Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.00000138 AC: 2AN: 1448114Hom.: 0 Cov.: 30 AF XY: 0.00000278 AC XY: 2AN XY: 720218
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152032Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74244
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:5
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 22, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 20, 2023 | Variant summary: CFTR c.1766G>A (p.Ser589Asn) results in a conservative amino acid change located in the ABC transporter-like, ATP-binding domain (IPR003439) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. As the variant alters the last conserved nucleotide of exon 13 adjacent to the canonical splice donor site, several computational tools predict a significant impact on normal splicing: Three predict the variant weakens the canonical 5' splicing donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing by severely reducing exon inclusion (FernandezAlanis_2012). The variant was absent in 249234 control chromosomes. c.1766G>A has been reported in the literature as a homozygous or compound heterozygous genotype in multiple individuals affected with Cystic Fibrosis (example, Stanziale_2005, Merelle_2006, Nunes_2017, Miller_2019). These data indicate that the variant is very likely to be associated with disease. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (P/LP, n=4; VUS, n=1). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | Nov 05, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 25, 2020 | The c.1766G>A pathogenic mutation (also known as p.S589N), located in coding exon 13 of the CFTR gene, results from a G to A substitution at nucleotide position 1766. The serine at codon 589 is replaced by asparagine, an amino acid with highly similar properties. However, this change occurs in the last base pair of coding exon 13, which makes it likely to have some effect on normal mRNA splicing. This mutation was detected in the homozygous state in a patient with pulmonary and gastrointestinal symptoms of cystic fibrosis (CF); both parents were confirmed heterozygous for the mutation (Stanziale et al. Genet Test. 2005;9:28). This variant has also been detected in additional individuals reported to have CF or related features who had a second mutation detected; however, in some cases, clinical detail was limited including phase determination (Mérelle ME et al. Acta Paediatr, 2006 Nov;95:1424-8; Nunes LM et al. Pediatr Pulmonol, 2017 10;52:1300-1305; Møller SA et al. J Cyst Fibros, 2019 09;18:657-66). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. In a minigene assay, this variant was indicated to result in exon skipping (Fernandez Alanis E et al. Hum Mol Genet, 2012 Jun;21:2389-98). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 03, 2023 | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 589 of the CFTR protein (p.Ser589Asn). RNA analysis indicates that this missense change induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with cystic fibrosis (PMID: 16379540, 30711384; Invitae). This variant is also known as G1898A. ClinVar contains an entry for this variant (Variation ID: 53382). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The asparagine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this missense change results in skipping of exon 12, but is expected to preserve the integrity of the reading-frame (PMID: 22362925). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jun 26, 2024 | The CFTR c.1766G>A (p.Ser589Asn) variant has been reported in the published literature in individuals affected with cystic fibrosis (CF) in a homozygous (PMID: 16379540 (2005)) and compound heterozygous state (PMID: 28771972 (2017), 36102402 (2022), 36369753 (2022)). Results from a minigene assay suggest this variant leads to exclusion of exon 12, however more evidence is needed to conclude this variant is damaging to protein function (PMID: 22362925 (2012)). The frequency of this variant in the general population (Genome Aggregation Database, http://gnomad.broadinstitute.org) is uninformative in the assessment of its pathogenicity. Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on splicing yielded predictions that this variant may affect proper CFTR mRNA splicing. Based on the available information, this variant is classified as likely pathogenic. - |
CFTR-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jun 21, 2019 | - - |
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 11, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at